Annales De Dermatologie Et De Venereologie最新文献

英文中文

Pruriginous vesicular eruption associated with nivolumab immunotherapy: A case of dermatitis herpetiformis 与 nivolumab 免疫疗法相关的瘙痒性水泡疹：一例疱疹性皮炎病例

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-04-27 DOI: 10.1016/j.annder.2024.103269

M. Housset, A. Fayad Kazour, C. Paugam, Y. Le Corre, A. Croue, L. Martin, D. Lechevalier, C. Berthin

引用次数: 0

Vestibulodynia: Clinical characteristics, first-line treatments, and factors associated with escalation of treatment with EMG–guided injections of botulinum toxin in a retrospective french cohort study 眩晕症：一项回顾性法国队列研究中的临床特征、一线治疗方法以及与肌电图引导下注射肉毒杆菌毒素治疗升级相关的因素

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-04-27 DOI: 10.1016/j.annder.2024.103277

C. Neuville , B. Parratte , S. Lombion , F. Aubin , I. Gallais Sérézal , F. Pelletier

Background

Vestibulodynia is a highly prevalent chronic pain disorder affecting the vulva having a major impact on women’s physical, psychological, and sexual well-being. It remains an underrecognized disease that responds insufficiently to therapies such as physiotherapy and medication.

Aim

To assess the global efficacy of first-line therapies and factors associated with treatment escalation in women with vestibulodynia.

Patients and methods

This retrospective cohort study was conducted at the dermatology outpatient clinic of the University Hospital in Besancon (France) between 2013 and 2017 and follow-up until 2021.

Results

Among 132 patients, the mean [standard deviation] age at diagnosis was 27.2 [±9.45] years, with an average duration of symptoms of 42.3 [±37.92] months. Most cases comprised provoked (75.0%) or secondary (72.7%) vestibulodynia. At least one comorbid pain or psychologic condition was identified respectively in 63 (47.7%) and 23 patients (54.5%). Vulvar hyperesthesia associated with pelvic floor muscle dysfunction was present in 121 patients (91.6%) and vulvar erethism was noted in 94 patients (71.2%). First-line treatments consisted of pelvic floor physiotherapy with biofeedback in 85% of patients, associated with amitriptyline in 36% of cases, and of additional lidocaine cream in 17%. Fifty-two patients (39%) presented at least a good response to first-line treatment, with only 21 (15%) being in complete remission, irrespective of therapeutic strategy (p = 0.25). Botulinum toxin injections were performed in 54 patients. Patients with either primary vestibulodynia (p = 0.04) or spontaneous vestibulodynia (p = 0.03) were more likely to receive this treatment.

Conclusion

Our study highlights the current lack of efficacy of first-line treatments in vestibulodynia. Considering the high prevalence of muscular dysfunction, botulinum toxin injections are of particular interest despite a lack of randomized controlled trials in this indication.

背景膀胱阴道炎是一种影响外阴的高发慢性疼痛疾病，对女性的生理、心理和性健康有重大影响。目的评估前庭大腺炎女性患者一线疗法的总体疗效以及与治疗升级相关的因素。结果132名患者中，平均[标准差]诊断年龄为27.2 [±9.45]岁，平均症状持续时间为42.3 [±37.92]个月。大多数病例为诱发性（75.0%）或继发性（72.7%）前庭大腺炎。63名患者（47.7%）和23名患者（54.5%）至少合并一种疼痛或心理疾病。121名患者（91.6%）出现与盆底肌肉功能障碍相关的外阴过度收缩，94名患者（71.2%）出现外阴糜烂。85%的患者接受了带生物反馈的盆底物理治疗，36%的患者接受了阿米替林治疗，17%的患者接受了额外的利多卡因乳膏治疗。52名患者（39%）对一线治疗至少有良好反应，只有21名患者（15%）完全缓解，与治疗策略无关（P = 0.25）。54名患者接受了肉毒杆菌毒素注射。原发性前庭神经痛（p = 0.04）或自发性前庭神经痛（p = 0.03）的患者更有可能接受这种治疗。考虑到肌肉功能障碍的高发病率，肉毒杆菌毒素注射尤其值得关注，尽管在这一适应症方面缺乏随机对照试验。

{"title":"Vestibulodynia: Clinical characteristics, first-line treatments, and factors associated with escalation of treatment with EMG–guided injections of botulinum toxin in a retrospective french cohort study","authors":"C. Neuville , B. Parratte , S. Lombion , F. Aubin , I. Gallais Sérézal , F. Pelletier","doi":"10.1016/j.annder.2024.103277","DOIUrl":"https://doi.org/10.1016/j.annder.2024.103277","url":null,"abstract":"<div><h3>Background</h3><p>Vestibulodynia is a highly prevalent chronic pain disorder affecting the vulva having a major impact on women’s physical, psychological, and sexual well-being. It remains an underrecognized disease that responds insufficiently to therapies such as physiotherapy and medication.</p></div><div><h3>Aim</h3><p>To assess the global efficacy of first-line therapies and factors associated with treatment escalation in women with vestibulodynia.</p></div><div><h3>Patients and methods</h3><p>This retrospective cohort study was conducted at the dermatology outpatient clinic of the University Hospital in Besancon (France) between 2013 and 2017 and follow-up until 2021.</p></div><div><h3>Results</h3><p>Among 132 patients, the mean [standard deviation] age at diagnosis was 27.2 [±9.45] years, with an average duration of symptoms of 42.3 [±37.92] months. Most cases comprised provoked (75.0%) or secondary (72.7%) vestibulodynia. At least one comorbid pain or psychologic condition was identified respectively in 63 (47.7%) and 23 patients (54.5%). Vulvar hyperesthesia associated with pelvic floor muscle dysfunction was present in 121 patients (91.6%) and vulvar erethism was noted in 94 patients (71.2%). First-line treatments consisted of pelvic floor physiotherapy with biofeedback in 85% of patients, associated with amitriptyline in 36% of cases, and of additional lidocaine cream in 17%. Fifty-two patients (39%) presented at least a good response to first-line treatment, with only 21 (15%) being in complete remission, irrespective of therapeutic strategy (<em>p</em> = 0.25). Botulinum toxin injections were performed in 54 patients. Patients with either primary vestibulodynia (<em>p</em> = 0.04) or spontaneous vestibulodynia (<em>p</em> = 0.03) were more likely to receive this treatment.</p></div><div><h3>Conclusion</h3><p>Our study highlights the current lack of efficacy of first-line treatments in vestibulodynia. Considering the high prevalence of muscular dysfunction, botulinum toxin injections are of particular interest despite a lack of randomized controlled trials in this indication.</p></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"151 2","pages":"Article 103277"},"PeriodicalIF":0.9,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140650910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Panitumumab-induced perforating collagenosis 帕尼单抗诱发的穿孔性胶原病

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-04-27 DOI: 10.1016/j.annder.2024.103271

N. Kluger, S. Jokela, L. Tolkki

引用次数: 0

Routine dermatology training and tele-expertise for general practitioners 为全科医生提供常规皮肤病学培训和远程专家培训

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-04-27 DOI: 10.1016/j.annder.2024.103266

P. Senet

引用次数: 0

Tele-expertise assessment of chronic wounds by advanced practice dermatology nurses 皮肤科高级护士对慢性伤口进行远程专家评估

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-04-27 DOI: 10.1016/j.annder.2024.103273

C. Robin , L. Poiroux , J. Delaunay , P. Seuwou , L. Martin , E. Démoulins

引用次数: 0

A rare case of granular parakeratosis of the glans resembling genital psoriasis 一例罕见的类似生殖器银屑病的龟头颗粒状角化不全病例

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-04-27 DOI: 10.1016/j.annder.2024.103268

A. Badaoui, I. Moulonguet

引用次数: 0

Electrosurgery in the treatment of pedunculated rhinophyma 电外科手术治疗有蒂鼻炎

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-04-26 DOI: 10.1016/j.annder.2024.103270

M. Dultra, P. Barros, A. Ivanchuk, J.R. Pegas

引用次数: 0

Real-life management of psoriasis with biological agents during pregnancy 孕期使用生物制剂治疗银屑病的实际情况

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-03-29 DOI: 10.1016/j.annder.2024.103254

C. Tran , E. Mahé , M. Beylot-Barry , D. Jullien , M.-A. Richard , A.-C. Fougerousse , A. Bouznad , C. Bulai Livideanu , A. Brun , F. Amelot , F. Maccari , F. Aubin , F. Benhadou , C. Paul

Background

French guidelines recommend stopping biologic treatment of psoriasis between 3 and 24 weeks before conception in accordance with the relevant Summary of Product Characteristics (SmPC). The aim of this study was to evaluate the real-life practice of dermatologists in the management of pregnant women with psoriasis previously treated with biologic agents. We wished to assess the level of practitioner adherence to the relevant SmPCs.

Material and methods

We conducted a study in collaboration with GRPso and Resopso. A computerized questionnaire was completed by the practitioners. We performed descriptive statistics and studied the profile of the practitioners, their level of confidence with continuation of biological agents during pregnancy, and their reported practices on the use of biological agents in pregnancy. Statistical analyses were performed using XLSTAT. A p-value of less than 0.05 was considered significant.

Results

A total of 63 dermatologists (women: 71%; mean age 43.8 years) participated in this study, the majority of whom were hospital-based (87%). Recommendations were followed by 36.5% of practitioners, while 44% reported discontinuing biologic agents on diagnosis of pregnancy, and 20.5% reported using these agents during pregnancy. Among dermatologists with more than ten years of experience, 19% reported following the SmPC. Among dermatologists with a patient base >200 (patients treated with biologic agents for psoriasis), 19% reported following the SmPC compared to 54% of practitioners with less than 50 patients. The mean age of dermatologists following the SmPC was 41 years vs. 47 years for those not following the SmPC.

Discussion

The majority of practitioners do not follow recommendations on discontinuation of biologic agents before the planning of pregnancy by patients.

背景法国指南建议，根据相关的产品特性摘要（SmPC），在受孕前 3 至 24 周停止银屑病的生物制剂治疗。本研究旨在评估皮肤科医生在治疗曾接受过生物制剂治疗的银屑病孕妇时的实际做法。材料与方法我们与 GRPso 和 Resopso 合作开展了一项研究。从业人员填写了一份电脑问卷。我们进行了描述性统计，并研究了从业人员的概况、他们对孕期继续使用生物制剂的信心程度以及他们报告的孕期使用生物制剂的做法。我们使用 XLSTAT 进行了统计分析。结果共有 63 名皮肤科医生（女性：71%；平均年龄 43.8 岁）参与了这项研究，其中大部分是医院医生（87%）。36.5%的医生遵循了建议，44%的医生在确诊怀孕后停用了生物制剂，20.5%的医生在怀孕期间使用了这些制剂。在拥有十年以上经验的皮肤科医生中，19% 的医生表示遵循了 SmPC 的建议。在拥有 200 名患者（使用生物制剂治疗银屑病的患者）的皮肤科医生中，19% 的医生表示遵循 SmPC，而在拥有不到 50 名患者的皮肤科医生中，54% 的医生表示遵循 SmPC。讨论大多数皮肤科医生没有遵循在患者计划怀孕前停用生物制剂的建议。

{"title":"Real-life management of psoriasis with biological agents during pregnancy","authors":"C. Tran , E. Mahé , M. Beylot-Barry , D. Jullien , M.-A. Richard , A.-C. Fougerousse , A. Bouznad , C. Bulai Livideanu , A. Brun , F. Amelot , F. Maccari , F. Aubin , F. Benhadou , C. Paul","doi":"10.1016/j.annder.2024.103254","DOIUrl":"https://doi.org/10.1016/j.annder.2024.103254","url":null,"abstract":"<div><h3>Background</h3><p>French guidelines recommend stopping biologic treatment of psoriasis between 3 and 24 weeks before conception in accordance with the relevant Summary of Product Characteristics (SmPC). The aim of this study was to evaluate the real-life practice of dermatologists in the management of pregnant women with psoriasis previously treated with biologic agents. We wished to assess the level of practitioner adherence to the relevant SmPCs.</p></div><div><h3>Material and methods</h3><p>We conducted a study in collaboration with GRPso and Resopso. A computerized questionnaire was completed by the practitioners. We performed descriptive statistics and studied the profile of the practitioners, their level of confidence with continuation of biological agents during pregnancy, and their reported practices on the use of biological agents in pregnancy. Statistical analyses were performed using XLSTAT. A p-value of less than 0.05 was considered significant.</p></div><div><h3>Results</h3><p>A total of 63 dermatologists (women: 71%; mean age 43.8 years) participated in this study, the majority of whom were hospital-based (87%). Recommendations were followed by 36.5% of practitioners, while 44% reported discontinuing biologic agents on diagnosis of pregnancy, and 20.5% reported using these agents during pregnancy. Among dermatologists with more than ten years of experience, 19% reported following the SmPC. Among dermatologists with a patient base >200 (patients treated with biologic agents for psoriasis), 19% reported following the SmPC compared to 54% of practitioners with less than 50 patients. The mean age of dermatologists following the SmPC was 41 years vs. 47 years for those not following the SmPC.</p></div><div><h3>Discussion</h3><p>The majority of practitioners do not follow recommendations on discontinuation of biologic agents before the planning of pregnancy by patients.</p></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"151 2","pages":"Article 103254"},"PeriodicalIF":0.9,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140328083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolution of rituximab use over time in moderate-to-severe pemphigus: A two-centre retrospective study 中重度丘疹性荨麻疹患者使用利妥昔单抗的演变：一项双中心回顾性研究

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-03-28 DOI: 10.1016/j.annder.2024.103265

M. Hazard, C. Bedane, O. Ducharme, P. Bernard, A.-L. Pham-Ledard

引用次数: 0

Pemphigoid of the pulmonary system 肺部系统丘疹性脓疱病

IF 0.9 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie

Pub Date : 2024-03-28 DOI: 10.1016/j.annder.2024.103253

A.R. Ahmed, M. Kalesinskas

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Annales De Dermatologie Et De Venereologie

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀